Description of possible adverse reactions of Quizartinib

Quizartinib ( Quizartinib), as a tyrosine kinase inhibitor targeting FLT3-ITD mutation, although has significant efficacy in acute myeloid leukemia (AML), certain adverse reactions may still occur during clinical use and require close monitoring during treatment. The most common side effects mainly involve the blood system, heart, electrolytes and gastrointestinal tract.

In terms of hematology, patients may develop myelosuppression manifested as neutropenia, thrombocytopenia, and anemia while receiving quizartinib. These hematological abnormalities may increase the risk of infection, bleeding, and anemia symptoms, so regular complete blood count monitoring is often required during treatment, and dosage adjustments or dosing delays are often required based on the blood count.

In terms of the cardiovascular system, quizartinib may causeQT interval prolongation, which is an electrophysiological change on the electrocardiogram that may increase the risk of arrhythmia if not detected in time. Clinical practice generally recommends regular monitoring of electrocardiograms and electrolyte levels before starting and during treatment, and taking additional precautions in patients with existing or high-risk cardiac disease.

Gastrointestinal reactions are also common adverse reactions, including nausea, vomiting, diarrhea or loss of appetite. Although these symptoms are generally controllable, they will affect the patient's quality of life and require appropriate symptomatic treatment, such as the use of anti-nausea drugs, maintenance of water and electrolyte balance, etc. Other possible adverse reactions include fever, fatigue, elevated liver enzymes, and rash. Patients should report abnormal symptoms in a timely manner during use, and the doctor will comprehensively evaluate whether to adjust the dose or interrupt treatment.

Of note, the severity of adverse reactions varies among individual patients, including age, underlying medical conditions, and prior treatment history. Usually, when serious adverse events occur, clinical intervention will be carried out by discontinuing the drug, reducing the dosage, or delaying the administration to ensure patient safety and maintain the therapeutic effect.

References:https://www.drugs.com/mtm/quizartinib.html